- Home
- ADCT vs MSD Comparison
ADCT vs MSD Comparison
Compare ADCT & MSD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADCT
- MSD
- Stock Information
- Founded
- ADCT 2011
- MSD 1993
- Country
- ADCT Switzerland
- MSD United States
- Employees
- ADCT N/A
- MSD N/A
- Industry
- ADCT Biotechnology: Pharmaceutical Preparations
- MSD Trusts Except Educational Religious and Charitable
- Sector
- ADCT Health Care
- MSD Finance
- Exchange
- ADCT Nasdaq
- MSD Nasdaq
- Market Cap
- ADCT 131.8M
- MSD 144.6M
- IPO Year
- ADCT 2020
- MSD N/A
- Fundamental
- Price
- ADCT $1.21
- MSD $7.42
- Analyst Decision
- ADCT Strong Buy
- MSD
- Analyst Count
- ADCT 5
- MSD 0
- Target Price
- ADCT $7.75
- MSD N/A
- AVG Volume (30 Days)
- ADCT 373.9K
- MSD 70.2K
- Earning Date
- ADCT 05-05-2025
- MSD 01-01-0001
- Dividend Yield
- ADCT N/A
- MSD 11.26%
- EPS Growth
- ADCT N/A
- MSD N/A
- EPS
- ADCT N/A
- MSD N/A
- Revenue
- ADCT $70,837,000.00
- MSD N/A
- Revenue This Year
- ADCT $6.82
- MSD N/A
- Revenue Next Year
- ADCT $18.56
- MSD N/A
- P/E Ratio
- ADCT N/A
- MSD N/A
- Revenue Growth
- ADCT 1.84
- MSD N/A
- 52 Week Low
- ADCT $1.05
- MSD $6.11
- 52 Week High
- ADCT $5.17
- MSD $7.46
- Technical
- Relative Strength Index (RSI)
- ADCT 39.36
- MSD 39.68
- Support Level
- ADCT $1.13
- MSD $6.91
- Resistance Level
- ADCT $1.25
- MSD $7.52
- Average True Range (ATR)
- ADCT 0.11
- MSD 0.23
- MACD
- ADCT 0.00
- MSD -0.02
- Stochastic Oscillator
- ADCT 39.51
- MSD 42.86
About ADCT ADC Therapeutics SA
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's product candidate includes ZYNLONTA, camidanlumab tesirine, ADCT-602, ADCT-601, ADCT-901, ADCT-701 and ADCT-212.
About MSD Morgan Stanley Emerging Markets Debt Fund Inc.
Morgan Stanley Emerg Mkts Debt Fd Inc is a diversified, closed-end management investment company. The Fund's primary investment objective is to produce high current income and as a secondary objective to seek capital appreciation, through investments mainly in debt securities of government and government-related issuers located in emerging countries, of entities organized to restructure the outstanding debt of such issuers and debt securities of corporate issuers in or organized under the laws of emerging countries.